Investments & digital assets › F8949.D.X3
F8949.D.X3 · federal · F8949 line D.X3
Delmar Pharma (acquired 2024-08-01, sold 2025-09-29; proceeds 282.95, basis 251.15)
31.80
engine v3
not yet verified
How this number was built
R-8949-LOT One line per sale: proceeds minus basis plus adjustment. Broker basis is used as reported unless a supplemental statement for the same lot is matched.
Sources (6) — where the inputs came from
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 20 · field X3_desc · “Lot X3 description”
read as “Delmar Pharma” → Delmar Pharma
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 20 · field X3_acq · “Lot X3 date acquired”
read as “08/01/2024” → 2024-08-01
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 20 · field X3_sold · “Lot X3 date sold”
read as “09/29/2025” → 2025-09-29
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 20 · field X3_proceeds · “Lot X3 proceeds”
read as “282.95” → 282.95
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 20 · field X3_basis · “Lot X3 cost basis”
read as “251.15” → 251.15
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 20 · field X3_wash · “Lot X3 wash sale loss disallowed”
read as “0.00” → 0
99%
Flows into
History — nothing is overwritten
v1 · 2026-03-04: 31.80v2 · 2026-03-19: 31.80v3 · 2026-06-23: 31.80
Adjust this number
Evidence & discussion
Record how you verified it